Biodel's Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
Biodel Inc. (Nasdaq: BIOD) announced today that it has received a notice of allowance from the European Patent Office for patent claims covering Biodel's ultra-rapid-acting insulin formulations intended for the treatment of patients with diabetes. The allowed claims cover formulations containing insulin or an insulin analog as an active agent, in which hexameric insulin dissociates to monomeric or dimeric forms. The formulations are in different forms for subcutaneous or sublingual delivery. Method claims cover use of these formulations to treat patients with Type 1 or Type 2 diabetes by subcutaneous or sublingual delivery. Once issued, the claims will have a term that expires in 2025—twenty years from the filing date of the previously issued parent patent.
Biodel's proprietary formulations allow insulin and insulin analogs to disassociate from the six molecule (hexameric) form to low molecular weight forms (dimeric or monomeric forms) and stabilize the low molecular weight forms, minimizing re-association to the hexameric form. It is believed that this promotes more rapid delivery of insulin into the blood when compared to currently marketed rapid-acting insulin analogs and produces desired biological effects.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.